MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1038/s42255-026-01578-w

Медицинская библиотека · Nature metabolism · 2026

Mitochondrial metabolism determines chemotherapy sensitivity in colorectal cancer.

Moss Deborah Y, Brown Connor N, Shaw Andrew M, McCann Christopher, Lewis Nikita, Downs Matilda, Wurelly Rebecca, Cunningham Ciara, Philips Aaron, Doherty Niamh, Gallagher Sarah, McDaid William J, Roe Andrew, Coughlan Aisling Y, Cavanagh Brenton, Ormsby Callum, Falcone Fiammetta, McCole Rachel, Monteith Scott, Rogan Emily, Malla Sudhir B, Emerson Alexandra J, Mohammed-Smith Letitia, Sharkey Shaun, Leonard Aoife, Gallagher Peter F, Banerjee Arindam, Van Schaeybroeck Sandra, Pandor Sufyan, Quinn Brian, Greer Brett, Elliott Christopher, Maguire Sarah, Ryan Aideen E, Dunne Philip D, Mallon Mary, Craig Stephanie, Aftab Omar, Greaves Laura C, Marzullo Bryan P, Tennant Daniel A, Coyle Vicky, Mills Ian G, Sansom Owen, Ní Chonghaile Tríona, Longley Daniel B, McDade Simon S, LaBonte Melissa J, Kerr Emma M

СтатьяПеревод пока не подготовлен

Аннотация

Therapy resistance is attributed to over 80% of cancer deaths per year, emphasizing the urgent need to overcome this challenge for improved patient outcomes. Despite its widespread use in colorectal cancer (CRC) treatment, resistance to 5-fluorouracil (5FU) remains poorly understood. As an antimetabolite, 5FU imposes substantial metabolic stress, forcing cells that survive treatment to rapidly adapt. We explored acute 5FU-driven changes in mitochondria, the organelle critical for coordinating metabolic stress responses. Here we demonstrate in a range of CRC models that 5FU treatment promotes mitochondrial biogenesis and increases mitochondrial function in surviving cells. Furthermore, we show that targeting mitochondrial metabolism, particularly by inhibiting Complex I, sensitizes CRC cells to 5FU, resulting in delayed tumour growth and prolonged survival in preclinical models. Additionally, analysis of patient data suggests that oxidative metabolism signatures may predict responses to 5FU-based chemotherapy. These findings shed light on mechanisms underlying 5FU resistance and propose a rational strategy for combination therapy in CRC, emphasizing the potential clinical benefit of targeting mitochondrial metabolism to overcome resistance and enhance patient outcomes.

Для цитирования: Moss Deborah Y, Brown Connor N, Shaw Andrew M, McCann Christopher, Lewis Nikita, Downs Matilda, Wurelly Rebecca, Cunningham Ciara, Philips Aaron, Doherty Niamh, Gallagher Sarah, McDaid William J, Roe Andrew, Coughlan Aisling Y, Cavanagh Brenton, Ormsby Callum, Falcone Fiammetta, McCole Rachel, Monteith Scott, Rogan Emily, Malla Sudhir B, Emerson Alexandra J, Mohammed-Smith Letitia, Sharkey Shaun, Leonard Aoife, Gallagher Peter F, Banerjee Arindam, Van Schaeybroeck Sandra, Pandor Sufyan, Quinn Brian, Greer Brett, Elliott Christopher, Maguire Sarah, Ryan Aideen E, Dunne Philip D, Mallon Mary, Craig Stephanie, Aftab Omar, Greaves Laura C, Marzullo Bryan P, Tennant Daniel A, Coyle Vicky, Mills Ian G, Sansom Owen, Ní Chonghaile Tríona, Longley Daniel B, McDade Simon S, LaBonte Melissa J, Kerr Emma M. Mitochondrial metabolism determines chemotherapy sensitivity in colorectal cancer.. Nature metabolism. 2026. DOI: 10.1038/s42255-026-01578-w.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.